2024 Mitsui Chemicals Catalysis Science Awards
1.8.2023 12:00:00 EEST | Business Wire | Press release
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) today announced that online applications for the 2024 Mitsui Chemicals Catalysis Science Awards will open on September 1, 2023.
Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 30 researchers within Japan and overseas. The application requirements for the 2024 Mitsui Chemicals Catalysis Science Awards are outlined below.
We welcome applications from a wide range of R&D fields, including solid catalysts, molecular catalysts and biocatalysts, as well as green processes and rare metal utilization via catalysis, along with materials science and development through novel catalysis.
The Mitsui Chemicals Catalysis Science Awards:
https://jp.mitsuichemicals.com/en/techno/csa/index.htm
I. Outline of awards
|
|
Mitsui Chemicals Catalysis Science Award |
Mitsui Chemicals Catalysis Science Award for Creative Work |
|
Eligible applicants |
Researchers affiliated to a university or public research institution, who have demonstrated extraordinary achievements in the field of catalysis science research (prize may be awarded to up to one winner) |
Researchers affiliated to a university or public research institution, who have demonstrated creative achievements in the field of catalysis science research (prize may be awarded to up to two winners) |
|
Application requirements |
Applicants must be no more than 47 years old as of April 1, 2023 |
Applicants must be no more than 37 years old as of April 1, 2023 |
|
Prize |
A plaque and prize money of 5 million yen |
A plaque and prize money of 1 million yen |
II. Schedule and selection process
|
Applications open |
September 1, 2023 |
|
Applications close |
December 31, 2023 |
|
Selection process |
Winners will be chosen by a selection committee organized by Mitsui Chemicals, consisting of several eminent academics in the field of catalysis science and a Mitsui Chemicals representative. |
|
Announcement of winners |
In June 2024 or thereabouts (details will be published on the website and in professional journals, among other sources) |
Please review the information at the link above for further details of the application process, including the application documents and information to be submitted, important notes concerning applications and information on the handling of personal information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801163348/en/
Contact information
Contacts for inquiries
Corporate Communication Div.
Mitsui Chemicals, Inc.
URL: https://form.mitsuichemicals.com/corporate/cc_pr_csr_en
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 16:36:00 EEST | Press release
MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also incl
Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 16:00:00 EEST | Press release
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction Transactions Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million. Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million. “Our year-to-date share repurchases
rhode Announces Official Launch Date for Its Retail Expansion in Europe with Sephora31.8.2026 16:00:00 EEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), today announced its collection of high-performance, skin-focused products will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831869746/en/ rhode will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026 Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode remains the No.1 overall skincare
Laboratory Modernization Strengthens QPS Holdings, LLC’s Long-Term Commitment to Elemental Bioanalysis31.8.2026 16:00:00 EEST | Press release
QPS Holdings, LLC (QPS) today announced a significant renewal of its elemental bioanalysis infrastructure through the acquisition of two PerkinElmer NexION® 2200 inductively coupled plasma mass spectrometry (ICP-MS) systems to be housed in its Netherlands laboratories. The new instruments will replace two Agilent 7700 ICP-MS systems currently operating within the bioanalysis department. The NexION® 2200 platform was selected to support robust trace-element analysis, effective management of analytical interferences, reliable performance with challenging sample matrices, and efficient laboratory operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831322534/en/ Daniel Schulz-Jander, QPS Senior Director, Bioanalysis The investment is part of a broader upgrade and renewal program focused on maintaining a modern, reliable, and sustainable mass spectrometry capabilities across QPS global laboratory facilities. In addition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
